Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.

Jaleh Fallah,Haley Gittleman,Chana Weinstock,Erik Bloomquist,Elaine Chang,Daniel L. Suzman,Sundeep Agrawal,Amna Ibrahim,Shenghui Tang,Richard Pazdur,Julia A. Beaver,Laleh Amiri-Kordestani

Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.

2021

Jaleh Fallah
Haley Gittleman
Chana Weinstock
Erik Bloomquist
Elaine Chang
Daniel L. Suzman
Sundeep Agrawal
Amna Ibrahim
Shenghui Tang
Richard Pazdur
Julia A. Beaver
Laleh Amiri-Kordestani

4516Background: Immunotherapy-based combination therapies (IO-X) are standard of care for metastatic RCC (mRCC) in the frontline setting. Limited data is available on the role of cytoreductive neph...

Keywords:

Nephrectomy
Medicine
Internal medicine
pooled analysis
in patient
Renal cell carcinoma
Oncology
survival benefit
standard of care
Immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations